Lawrence Rosen & Paragon Therapeutics
3 shared events · Importance 3 · Last updated Sep 11, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
Lawrence Rosen: Lawrence Rosen is a founding partner of Rosen Law Firm and a contact for the class action. His involvement is peripheral to the market impact of the event.
Paragon Therapeutics: Capricor is the defendant in the securities class action, facing allegations of misleading investors regarding its Deramiocel BLA and statistical analysis plan changes. The lawsuit and upcoming lead plaintiff deadline could negatively affect its stock price and reputation.
Sep 21, 2026 · 6 articles
Regulatory
Lawrence Rosen: Partner at Rosen Law Firm involved in the lawsuit.
Paragon Therapeutics: Central company facing regulatory rejection and multiple securities fraud lawsuits; stock collapsed over 78%.
Jul 27, 2026 · 305 articles
Regulatory
Lawrence Rosen: Founding partner of Rosen Law Firm, which issued investor alerts on the class action.
Paragon Therapeutics: Capricor is the central defendant in the securities fraud class action and the issuer whose Deramiocel BLA and statistical analysis plan changes are at the heart of the dispute. The litigation, the 64% stock drop, and the extended PDUFA date to November 22, 2026 leave its equity under heavy pressure and its regulatory path uncertain.
Aug 10, 2026 · 267 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how Lawrence Rosen and Paragon Therapeutics interact across events, view sentiment trends, and discover connected entities.
Open Dashboard